Molecular Imaging of Neoplasia Using Nanoparticles

Information

  • Research Project
  • 6550007
  • ApplicationId
    6550007
  • Core Project Number
    R43CA091724
  • Full Project Number
    1R43CA091724-01A1
  • Serial Number
    91724
  • FOA Number
    PA-00-18
  • Sub Project Id
  • Project Start Date
    8/12/2002 - 22 years ago
  • Project End Date
    7/31/2003 - 21 years ago
  • Program Officer Name
    FARAHANI, KEYVAN
  • Budget Start Date
    8/12/2002 - 22 years ago
  • Budget End Date
    7/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/12/2002 - 22 years ago

Molecular Imaging of Neoplasia Using Nanoparticles

DESCRIPTION (provided by applicant):The long term goal of the present proposal is to develop a nanoparticle that can be targeted to tissues with specific molecular signatures. Inclusion of a contrast agent (Iron Oxide for MRI) within the nanoparticle would therefore facilitate non-invasive imaging of specific biochemical properties within tissues in-vivo. The present proposal is focused on investigating if a nanoparticle based contrast agent can be efficiently targeted to cells with specific molecular characteristics. Two well-characterized molecular targets will be investigated. The first involves targeting to endothelial cells that express alpha-V-beta-3 and alpha-V-beta-5 integrins using the sequence CDCRGDCFC. Expression of these integrins is a hallmark of endothelial cells within angiogenic vasculature (e.g. within tumors). Similarly, we will target tissues (endothelial cells and tumors) that are undergoing tissue remodeling. Since expression of the metalloproteases MMP-2 and MMP-9 is characteristic of cells that need to migrate through the extracellular matrix or basement membrane, inclusion of the CTTHWGFTLC within a nanoparticle will target nanoparticles to tumors and tumor vasculature that typically express these proteases. It is anticipated that the results from the proposed studies will provide the foundation for future development of these novel nano-structure-based strategies for non-invasive in vivo imaging of specific biochemical events.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    183548
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:183548\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOLECULAR THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    843026449
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48108
  • Organization District
    UNITED STATES